Loading...
XSWX
MED
Market cap1.42bUSD
Jul 09, Last price  
91.70CHF
1D
0.77%
1Q
12.38%
IPO
46.72%
Name

Medartis Holding AG

Chart & Performance

D1W1MN
XSWX:MED chart
P/E
136.70
P/S
4.24
EPS
0.67
Div Yield, %
Shrs. gr., 5y
1.13%
Rev. gr., 5y
16.10%
Revenues
269m
+19.76%
82,302,85092,502,392105,040,292121,324,702130,143,937127,645,985159,880,236182,824,418212,006,000224,831,000269,257,000
Net income
8m
+136.65%
7,270,9493,314,395866,5214,201,9072,146,521-943,5656,837,867-5,782,888619,0003,528,0008,349,000
CFO
35m
+8.56%
11,877,11711,908,64011,012,9946,449,4648,114,01712,610,80620,952,678-3,927,46019,980,00032,072,00034,817,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Medartis Holding AG is a global medical technology firm that develops, manufactures, and distributes implantable solutions. These advanced medical devices are utilized worldwide for the surgical stabilization of bone fractures in both the upper and lower extremities, in addition to addressing complex cranio-maxillofacial surgical needs. The company's portfolio features osteosynthesis instruments, marketed under the APTUS and MODUS brands, specifically designed for various body regions including the hand, wrist, elbow, shoulder, foot, and ankle, as well as for facial and skull procedures involving the mandible, midface, orthognathic structures, and cranium. Medartis serves a diverse clientele comprising surgeons, hospitals, medical centers, and group purchasing organizations. The company, founded in 1997, is headquartered in Basel, Switzerland.
IPO date
Mar 23, 2018
Employees
858
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT